Literature DB >> 15550053

Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis.

C Rus, M Bazzan, A Palumbo, S Bringhen, M Boccadoro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15550053     DOI： 10.1111/j.1538-7836.2004.00931.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  3 in total

Review 1.  Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.

Authors:  Nicole M Kuderer; Gary H Lyman
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

2.  Arterial thrombosis and thalidomide.

Authors:  Mustafa Goz; M Nesimi Eren; Omer Cakir
Journal:  J Thromb Thrombolysis       Date:  2008-04       Impact factor: 2.300

3.  Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques.

Authors:  Xionghu Yang; Nancy A Brandenburg; John Freeman; Maria Luisa Salomon; Jerome B Zeldis; Robert D Knight; Robert Bwire
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.